“Small molecule therapies will be with us for the foreseeable future, and will almost certainly continue to be used as first-line therapies for the next 10 years,” said Navin Molecular CCO Jordi Robinson, as part of our 10-year anniversary feature “The Multifaceted Future of Pharma.” Amongst the highly sophisticated and ever-evolving pipelines of biopharmaceuticals and cell and gene therapies, the stalwarts of pharmaceutical products – the small molecule medicines – remain. And not just remaining but witnessing a comeback as developers are returning to the small molecules modality, according to Adragos Pharma CEO Andreas Raabe: “Another big change the industry has seen is the shift away from biologics and cell gene therapy and back to traditional small molecules … as a scientist at heart, I stuck to my gut, which told me to stick with small molecules, and I am so happy that I did!” 

There is much happening in the small molecules world, so keep an eye on our web pages as we launch a new regular feature, “Small World,” which summarizes the ongoing achievements of the industry’s longest serving modality. As always, feel free to connect with me with your own news, views, and “don’ts-and-dos”: rob.coker@texerepublishing.com.